Advancing a novel product pipeline of neurology therapies
View Product PipelineAbout
We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders.
Our novel product pipeline addresses areas of high unmet medical need, with a focus on epilepsy.
Read MoreNews
Xenon Pharmaceuticals Announces Pricing of Upsized $300.0 Million Public Offering
November 29, 2023
Xenon Pharmaceuticals Announces Proposed Public Offering
November 29, 2023
Xenon Pharmaceuticals Announces Topline Results from Phase 2 Proof-of-Concept X-NOVA Clinical Trial of XEN1101 in Major Depressive Disorder (MDD)
November 27, 2023
Xenon Pharmaceuticals Provides Update on Partnered Program with Neurocrine Biosciences
November 9, 2023
Xenon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 8, 2023
Product Pipeline
XEN1101
for Focal Onset Seizures (FOS)
X-TOLE2/3 Clinical Trial
XEN1101
for Primary Generalized Tonic-Clonic Seizures (PGTCS)
X-ACKT Clinical Trial
XEN1101
for Major Depressive Disorder (MDD)
X-NOVA Clinical trial
XEN1101
for MDD
Investigator-led Phase 2 POC study Collaboration with Mount Sinai
NBI-921352
for Rare Pediatric Epilepsy: SCN8A-DEE
Partnered with Neurocrine Biosciences
Investors
Visit our Investor page for News Releases, Annual & Quarterly Reports, Webcasts & Events
View Investor Area
